Company intelligence / Profile preview

Medtric Biotech

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Medtric Biotech develops and commercializes antibiotic-free, environmentally friendly antimicrobial solutions based on a proprietary nanoemulsion platform. Their technology rapidly kills multidrug-resistant bacteria, fungi, and viruses by disrupting microbial membranes. The primary application has been advanced wound care with additional uses in industrial/agricultural disinfection. Scientific studies have shown rapid (<60 seconds) microbe inactivation including against MRSA/VRE.

Therapeutic areas: OtherInfectious Diseases
Modalities: Antimicrobial nanoemulsions (not traditional small molecules or biologics)
Industry: Consumable Medical Devices

Drug pipeline

1 asset

GoPlay

Commercial

Indications: Hand sanitization, Oral care

Beyond the preview

Go deeper on Medtric Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medtric Biotech.

Explore the full profile